Annual CFO
-$20.46 M
-$1.14 M-5.89%
31 December 2023
Summary:
Brainstorm Cell Therapeutics annual cash flow from operations is currently -$20.46 million, with the most recent change of -$1.14 million (-5.89%) on 31 December 2023. During the last 3 years, it has risen by +$14.73 million (+41.87%). BCLI annual CFO is now -292157.14% below its all-time high of -$7000.00, reached on 31 March 2003.BCLI Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$3.30 M
-$1.62 M-96.02%
30 September 2024
Summary:
Brainstorm Cell Therapeutics quarterly cash flow from operations is currently -$3.30 million, with the most recent change of -$1.62 million (-96.02%) on 30 September 2024. Over the past year, it has increased by +$3.11 million (+48.53%). BCLI quarterly CFO is now -185.84% below its all-time high of $3.84 million, reached on 30 September 2017.BCLI Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$11.33 M
+$3.11 M+21.54%
30 September 2024
Summary:
Brainstorm Cell Therapeutics TTM cash flow from operations is currently -$11.33 million, with the most recent change of +$3.11 million (+21.54%) on 30 September 2024. Over the past year, it has increased by +$10.49 million (+48.08%). BCLI TTM CFO is now -708025.00% below its all-time high of -$1600.00, reached on 30 June 2002.BCLI TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCLI Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.9% | +48.5% | +48.1% |
| 3 y3 years | +41.9% | +48.9% | +60.0% |
| 5 y5 years | -65.1% | +9.0% | +3.1% |
BCLI Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -5.9% | +41.9% | -96.0% | +51.3% | at high | +60.0% |
| 5 y | 5 years | -81.9% | +41.9% | -96.0% | +78.0% | -0.7% | +67.8% |
| alltime | all time | <-9999.0% | +41.9% | -185.8% | +78.0% | <-9999.0% | +67.8% |
Brainstorm Cell Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.30 M(+96.0%) | -$11.33 M(-21.5%) |
| June 2024 | - | -$1.68 M(-45.1%) | -$14.44 M(-26.1%) |
| Mar 2024 | - | -$3.06 M(-6.8%) | -$19.54 M(-4.5%) |
| Dec 2023 | -$20.46 M(+5.9%) | -$3.29 M(-48.7%) | -$20.46 M(-6.2%) |
| Sept 2023 | - | -$6.41 M(-5.4%) | -$21.82 M(+7.7%) |
| June 2023 | - | -$6.78 M(+70.0%) | -$20.26 M(+3.3%) |
| Mar 2023 | - | -$3.99 M(-14.2%) | -$19.62 M(+1.5%) |
| Dec 2022 | -$19.32 M(-26.4%) | -$4.65 M(-4.2%) | -$19.32 M(-4.3%) |
| Sept 2022 | - | -$4.85 M(-20.9%) | -$20.18 M(-7.4%) |
| June 2022 | - | -$6.13 M(+66.3%) | -$21.79 M(+3.8%) |
| Mar 2022 | - | -$3.69 M(-33.0%) | -$20.98 M(-20.1%) |
| Dec 2021 | -$26.27 M(-25.4%) | -$5.51 M(-14.7%) | -$26.27 M(-7.3%) |
| Sept 2021 | - | -$6.46 M(+21.2%) | -$28.34 M(-1.6%) |
| June 2021 | - | -$5.33 M(-40.6%) | -$28.80 M(-1.1%) |
| Mar 2021 | - | -$8.97 M(+18.3%) | -$29.13 M(-17.2%) |
| Dec 2020 | -$35.19 M(+212.9%) | -$7.58 M(+9.4%) | -$35.19 M(+13.9%) |
| Sept 2020 | - | -$6.92 M(+22.3%) | -$30.89 M(+12.0%) |
| June 2020 | - | -$5.66 M(-62.3%) | -$27.59 M(+8.5%) |
| Mar 2020 | - | -$15.03 M(+358.5%) | -$25.44 M(+126.2%) |
| Dec 2019 | -$11.25 M(-9.2%) | -$3.28 M(-9.6%) | -$11.25 M(-3.8%) |
| Sept 2019 | - | -$3.63 M(+3.4%) | -$11.69 M(-20.2%) |
| June 2019 | - | -$3.51 M(+320.1%) | -$14.66 M(+32.1%) |
| Mar 2019 | - | -$835.00 K(-77.6%) | -$11.10 M(-10.4%) |
| Dec 2018 | -$12.39 M(+424.0%) | -$3.72 M(-43.5%) | -$12.39 M(+6.8%) |
| Sept 2018 | - | -$6.59 M(<-9900.0%) | -$11.60 M(+897.4%) |
| June 2018 | - | $55.00 K(-102.6%) | -$1.16 M(-59.2%) |
| Mar 2018 | - | -$2.13 M(-27.6%) | -$2.85 M(+20.5%) |
| Dec 2017 | -$2.36 M(-59.6%) | -$2.94 M(-176.4%) | -$2.36 M(+278.2%) |
| Sept 2017 | - | $3.84 M(-335.8%) | -$625.00 K(-86.8%) |
| June 2017 | - | -$1.63 M(-0.7%) | -$4.74 M(+5.0%) |
| Mar 2017 | - | -$1.64 M(+37.3%) | -$4.52 M(-22.9%) |
| Dec 2016 | -$5.86 M(-20.9%) | -$1.20 M(+334.9%) | -$5.86 M(-1.6%) |
| Sept 2016 | - | -$275.00 K(-80.4%) | -$5.95 M(-27.5%) |
| June 2016 | - | -$1.41 M(-52.8%) | -$8.21 M(-2.9%) |
| Mar 2016 | - | -$2.98 M(+130.9%) | -$8.45 M(+14.1%) |
| Dec 2015 | -$7.41 M(+65.1%) | -$1.29 M(-49.0%) | -$7.41 M(-8.8%) |
| Sept 2015 | - | -$2.53 M(+53.3%) | -$8.12 M(+21.0%) |
| June 2015 | - | -$1.65 M(-14.8%) | -$6.71 M(+11.3%) |
| Mar 2015 | - | -$1.94 M(-3.5%) | -$6.03 M(+34.5%) |
| Dec 2014 | -$4.49 M(+10.7%) | -$2.01 M(+79.4%) | -$4.49 M(+9.8%) |
| Sept 2014 | - | -$1.12 M(+15.4%) | -$4.09 M(+11.0%) |
| June 2014 | - | -$970.00 K(+148.1%) | -$3.68 M(-2.5%) |
| Mar 2014 | - | -$391.00 K(-75.7%) | -$3.77 M(-6.9%) |
| Dec 2013 | -$4.05 M | -$1.61 M(+125.5%) | -$4.05 M(+29.0%) |
| Sept 2013 | - | -$713.00 K(-32.9%) | -$3.14 M(-10.3%) |
| June 2013 | - | -$1.06 M(+58.7%) | -$3.50 M(+22.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | -$670.00 K(-3.7%) | -$2.86 M(-2.6%) |
| Dec 2012 | -$2.94 M(+32.0%) | -$696.00 K(-35.2%) | -$2.94 M(+8.3%) |
| Sept 2012 | - | -$1.07 M(+156.3%) | -$2.71 M(+7.0%) |
| June 2012 | - | -$419.00 K(-43.8%) | -$2.53 M(-13.1%) |
| Mar 2012 | - | -$746.00 K(+58.4%) | -$2.91 M(+31.1%) |
| Dec 2011 | -$2.22 M(+7.4%) | -$471.00 K(-47.5%) | -$2.22 M(-3.3%) |
| Sept 2011 | - | -$897.00 K(+12.1%) | -$2.30 M(+27.6%) |
| June 2011 | - | -$800.00 K(+1354.5%) | -$1.80 M(+18.0%) |
| Mar 2011 | - | -$55.00 K(-89.9%) | -$1.53 M(-26.2%) |
| Dec 2010 | -$2.07 M(+178.1%) | -$546.00 K(+36.5%) | -$2.07 M(+12.8%) |
| Sept 2010 | - | -$400.00 K(-23.8%) | -$1.83 M(+11.4%) |
| June 2010 | - | -$525.00 K(-12.2%) | -$1.65 M(+39.6%) |
| Mar 2010 | - | -$598.00 K(+92.3%) | -$1.18 M(+58.6%) |
| Dec 2009 | -$744.00 K(-57.1%) | -$311.00 K(+46.0%) | -$744.00 K(+28.7%) |
| Sept 2009 | - | -$213.00 K(+267.2%) | -$578.00 K(-28.7%) |
| June 2009 | - | -$58.00 K(-64.2%) | -$811.00 K(-34.1%) |
| Mar 2009 | - | -$162.00 K(+11.7%) | -$1.23 M(-29.1%) |
| Dec 2008 | -$1.73 M(-2.3%) | -$145.00 K(-67.5%) | -$1.73 M(-6.9%) |
| Sept 2008 | - | -$446.00 K(-6.5%) | -$1.86 M(-21.3%) |
| June 2008 | - | -$477.00 K(-28.4%) | -$2.37 M(+7.9%) |
| Mar 2008 | - | -$666.00 K(+144.0%) | -$2.19 M(+23.6%) |
| Dec 2007 | -$1.77 M(+107.5%) | -$273.00 K(-71.2%) | -$1.77 M(+18.2%) |
| Sept 2007 | - | -$949.00 K(+212.3%) | -$1.50 M(+60.5%) |
| June 2007 | - | -$303.90 K(+22.5%) | -$935.00 K(-10.1%) |
| Mar 2007 | - | -$248.10 K(-35.2%) | -$1.04 M(-33.8%) |
| Dec 2006 | -$855.00 K(-31.7%) | - | - |
| Sept 2006 | - | -$383.00 K(-6.4%) | -$1.57 M(+6.6%) |
| June 2006 | - | -$409.00 K(0.0%) | -$1.47 M(+17.7%) |
| Mar 2006 | - | -$409.00 K(+10.2%) | -$1.25 M(+20.3%) |
| Mar 2006 | -$1.25 M(+84.8%) | - | - |
| Dec 2005 | - | -$371.10 K(+30.1%) | -$1.04 M(-9.8%) |
| Sept 2005 | - | -$285.30 K(+52.6%) | -$1.15 M(+32.0%) |
| June 2005 | - | -$186.90 K(-5.4%) | -$874.40 K(+29.0%) |
| Mar 2005 | -$677.80 K(+4301.3%) | -$197.60 K(-59.2%) | -$677.80 K(+39.1%) |
| Dec 2004 | - | -$484.30 K(+8548.2%) | -$487.20 K(+6146.2%) |
| Sept 2004 | - | -$5600.00(-157.7%) | -$7800.00(+44.4%) |
| June 2004 | - | $9700.00(-238.6%) | -$5400.00(-65.2%) |
| Mar 2004 | -$15.40 K(+120.0%) | -$7000.00(+42.9%) | -$15.50 K(+59.8%) |
| Dec 2003 | - | -$4900.00(+53.1%) | -$9700.00(+115.6%) |
| Sept 2003 | - | -$3200.00(+700.0%) | -$4500.00(-22.4%) |
| June 2003 | - | -$400.00(-66.7%) | -$5800.00(-17.1%) |
| Mar 2003 | -$7000.00(-5.4%) | -$1200.00(-500.0%) | -$7000.00(+20.7%) |
| Dec 2002 | - | $300.00(-106.7%) | -$5800.00(-4.9%) |
| Sept 2002 | - | -$4500.00(+181.3%) | -$6100.00(+281.3%) |
| June 2002 | - | -$1600.00 | -$1600.00 |
| Mar 2002 | -$7400.00 | - | - |
FAQ
- What is Brainstorm Cell Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics annual CFO year-on-year change?
- What is Brainstorm Cell Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics quarterly CFO year-on-year change?
- What is Brainstorm Cell Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics TTM CFO year-on-year change?
What is Brainstorm Cell Therapeutics annual cash flow from operations?
The current annual CFO of BCLI is -$20.46 M
What is the all time high annual CFO for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual cash flow from operations is -$7000.00
What is Brainstorm Cell Therapeutics annual CFO year-on-year change?
Over the past year, BCLI annual cash flow from operations has changed by -$1.14 M (-5.89%)
What is Brainstorm Cell Therapeutics quarterly cash flow from operations?
The current quarterly CFO of BCLI is -$3.30 M
What is the all time high quarterly CFO for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly cash flow from operations is $3.84 M
What is Brainstorm Cell Therapeutics quarterly CFO year-on-year change?
Over the past year, BCLI quarterly cash flow from operations has changed by +$3.11 M (+48.53%)
What is Brainstorm Cell Therapeutics TTM cash flow from operations?
The current TTM CFO of BCLI is -$11.33 M
What is the all time high TTM CFO for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high TTM cash flow from operations is -$1600.00
What is Brainstorm Cell Therapeutics TTM CFO year-on-year change?
Over the past year, BCLI TTM cash flow from operations has changed by +$10.49 M (+48.08%)